| Similar Articles |
|---|
 |
Chemistry World
December 3, 2013
Phillip Broadwith |
New wave of hepatitis C drugs hits US shore Johnson & Johnson's hepatitis C drug Olysio (simeprevir) has been approved by the US Food and Drug Administration.   |
Chemistry World
October 1, 2014
Phillip Broadwith |
J&J to buy antiviral specialist Alios Johnson and Johnson has agreed to buy antiviral specialist Alios BioPharma for $1.75 billion |
The Motley Fool
April 30, 2008
Brian Lawler |
Idenix Aims for a Comeback This drugmaker may be down, but it's not yet out. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
April 27, 2005
Charly Travers |
Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years. |
The Motley Fool
December 29, 2006
Brian Lawler |
Sirna Decides to Take the Cash and Run Shareholders vote to approve Merck's buyout offer. Investors in shares of Merck really have to trust management to have done its due diligence on Sirna and to have faith in its technology. |
The Motley Fool
January 9, 2012
Brian Orelli |
3 Reasons Hep C Premiums Might Not Last Careful what you wish for. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
July 7, 2011
Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. |
The Motley Fool
June 22, 2004
Charly Travers |
Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline. |
The Motley Fool
September 28, 2007
Brian Orelli |
Idenix Axes Ailing Initiatives The small drug developer drops its hepatitis B program, deciding instead to focus on its HCV and HIV drug development. Investors, take note. |
The Motley Fool
January 9, 2012
Travis Hoium |
Idenix Pharmaceuticals Shares Jumped: What You Need to Know Shares of Idenix Pharmaceuticals got a positive diagnosis today and climbed 43% after the company released positive data for its hepatitis C drug. |
The Motley Fool
September 7, 2007
Brian Orelli |
Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells. |
The Motley Fool
October 16, 2007
Brian Orelli |
Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
April 19, 2005
Charly Travers |
A Rising Star in Biotech Idenix is following a proven path to success: novel drug development. This is one biotech to keep on your watch list for the next year. |
Chemistry World
May 29, 2015
Phillip Broadwith |
Achillion partners with Janssen to boost hepatitis C pipeline Janssen will invest $225 million in Achillion shares, and has promised performance milestone payments worth up to $1.1 billion, plus royalties on any sales. |
The Motley Fool
June 15, 2007
Brian Lawler |
Idenix Gets Knocked Shares of Idenix drop slightly after the drug developer released clinical trial results this week. |
The Motley Fool
December 12, 2007
Brian Orelli |
What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010. |
Chemistry World
January 11, 2012
Andrew Turley |
BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection. |
The Motley Fool
November 30, 2011
Brian Orelli |
Up Big With Room to Run Lofty hep C valuations are par for the course. |
The Motley Fool
May 18, 2011
Brian Orelli |
If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship. |
The Motley Fool
December 16, 2011
Brian Orelli |
Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function. |
The Motley Fool
July 27, 2011
Alexander Crawford |
Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve? |
Chemistry World
December 9, 2009
Sarah Houlton |
New hep C breakthrough A drug being developed by Denmark's Santaris Pharma could provide a breakthrough in the treatment of hepatitis C, and positive results in a study on chimpanzees point to its potential to avoid drug resistance. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
July 16, 2007
Brian Lawler |
Idenix Gets Stopped It's been a bad two months for Idenix Pharmaceuticals. First, negative data for its hepatitis drug candidate, valopicitabine; now the FDA has put a stop to all testing of the drug. |
The Motley Fool
July 27, 2011
Brian Orelli |
Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Hepatitis C: Another Protease Revolution The launch of a new class of protease inhibitors is set to transform HCV treatment over the next decade, with kinder, gentler oral antiviral cocktails that will increase success rates from 50 percent to 75 percent. |
Chemistry World
April 21, 2010
Sarah Houlton |
Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials. |
The Motley Fool
October 19, 2007
Brian Lawler |
Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down. |
Pharmaceutical Executive
October 1, 2005 |
Successful Alliances: Novartis and Idenix Share the Secrets of Success Novartis Pharma AG CEO Thomas Ebeling and Idenix founder, CEO, and chairman Jean-Pierre Sommadossi discuss the mutual benefits and challenges of maintaining a successful partnership. |
The Motley Fool
June 14, 2011
Brian Orelli |
Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma. |
The Motley Fool
October 20, 2010
Brian Orelli |
What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back. |
The Motley Fool
October 27, 2011
Sean Williams |
Idenix Pharmaceuticals Shares Popped: What You Need to Know Shares of biopharmaceutical company Idenix Pharmaceuticals jumped as much as 26% earlier in the trading session before paring the majority of its gains despite any company-specific news. |
The Motley Fool
November 21, 2011
David Williamson |
Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977. |
Chemistry World
October 31, 2008
Matt Wilkinson |
GSK Snaps up Hepatitis Drug Developer In a bid to strengthen its efforts to develop new hepatitis therapies, GSK has agreed to buy Genelabs Technologies in a deal worth $57 million. |
The Motley Fool
October 31, 2011
Brian Orelli |
Gunning for the Leaders Hepatitis C drugs take center stage. |
Chemistry World
August 5, 2015
Rebecca Trager |
Grabbing slices of the immuno-oncology pie An increasing number of companies are competing for a slice of the immuno-oncology market |
The Motley Fool
April 6, 2011
Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
August 4, 2010
Brian Orelli |
No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's. |
The Motley Fool
June 5, 2009
Brian Orelli |
Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients. |
The Motley Fool
November 8, 2007
Brian Lawler |
Idenix Reels Itself In The small-cap drug developer cuts expenditures in the third quarter when sales of their hepatitis treatment don't materialize as quickly as hoped. Investors, take note. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
Fast Company
March 2015
J.J. McCorvey |
How Drug Company Gilead Outpaces Its Competitors -- And Common Diseases Over the past few years, Gilead has ushered through four effective new treatments for HIV alone. |
The Motley Fool
February 27, 2007
Brian Lawler |
Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors. |
The Motley Fool
December 21, 2006
Brian Lawler |
Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments. |
Chemistry World
August 27, 2014
Phillip Broadwith |
Clinical collaborations drive cancer immunotherapy A joint clinical trial agreement between Merck & Co and Pfizer is the latest in a rather tangled web of tie-ups between companies with cancer drugs that harness patients' immune systems. |
The Motley Fool
June 30, 2008
Brian Orelli |
A Drug to End Merck's Headache? Merck presents promising data for its phase 3 migraine drug. |
